Dr. Kass Discusses HER2-Positive Breast Cancer Advancements
Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses HER2-positive breast cancer advancements.
Kass says the adjuvant setting has produced positive results, which has allowed he and his colleagues to effectively palliate metastatic patients better than ever before. However, optimal sequencing is still being determined.
Some metastatic malignancies can now be managed as chronic illnesses, says Kass. By being able to control these malignancies, Kass and his colleagues are now seeing recurrences of metastases to the central nervous system (CNS) as the limiting factor for quality and quantity of life.
Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses HER2-positive breast cancer advancements.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Real-World Data and AI Help Improve ILD Management in HER2+ Breast Cancer
December 13th 2024Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can enhance adverse event monitoring and improve patient outcomes for those with HER2+ breast cancer.
Read More
